Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known Application Number 10/720.702 Filing Date November 24, 2003 First Named Inventor Jacques P. Dumas Art Unit 1621 Examiner Name Peter G. O'Sullivan Attorney Docket Number 5052D1(304795/69713 Div)

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (ff known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		<sup>US-</sup> 3,478,028	11/1969	Parsons et al.	
		<sup>US-</sup> 3,753,988	08/1973	Rodway et al.	
		<sup>US-</sup> 5,089,494	02/1992	Iwase et al.	
		<sup>US-</sup> 5,324,727	06/1994	Iwase et al.	
		<sup>US-</sup> 5,849,741	12/1998	Watanabe et al.	
		<sup>US-</sup> 6,288,064	09/2001	Watanabe et al.	
		US-			
		US-		-	
		US-			

		FORE	IGN PATENT DOC	JMENTS		
Examiner Cite No.1	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
		EP 0534443 A1	09/1993	Mitsubishi Chem Corp.		
		EP 0722936	07/1996	Eisai Co. Ltd.		
		EP 0920868	08/1997	Eisai Co. Ltd.		
		EP 0682947	09/1997	Mitsubishi Chem Corp.		
		EP 0534443 B1	12/1998	Mitsubishi Chem Corp.		
		FR 1453897	09/1966	Robba		

Examiner	Date	
Signature	Considered	
	00/10/40/04	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 

5052D1(304795/69713 Div)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/720,702 Filing Date November 24, 2003 INFORMATION DISCLOSURE First Named Inventor Jacques P. Dumas STATEMENT BY APPLICANT Art Unit 1621 (Use as many sheets as necessary) Examiner Name Peter G. O'Sullivan

Sheet 2

Attorney Docket Number

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan
		Number-Kind Code <sup>2 (if known)</sup>			Figures Appear
		US-			
-		US-			
H-14-1		US-			· · · · · · · · · · · · · · · · · · ·
		US-			

		FORE	IGN PATENT DOCI	JMENTS	· · · · · · · · · · · · · · · · · · ·	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
		FR 1516777	03/1968	Pons		
		JP 3106875	07/1991	Mitsubishi Materials		
		WO 0009495	02/1998	Novartis		
		WO 9835958	08/1998	Novartis		
		WO 9852944	11/1998	Sugen Inc.		
		WO 9858929	12/1998	Janssen Pharmaceutica		

Examiner	Date	
Signature	Considered	
	Contolacioa	1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	9	

Complete if Known					
Application Number	10/720,702				
Filing Date	November 24, 2003				
First Named Inventor	Jacques P. Dumas				
Art Unit	1621				
Examiner Name	Peter G. O'Sullivan				
Attorney Docket Number	5052D1(304795/69713 Div)				

			U. S. PATENT D		
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US-	<del> </del>		- I iguioo / (ppou)
	]	05-			
		US-			
·····		US-			
		US-			
· · · · · · · · · · · · · · · · · · ·		US-			
		US-			
		US-			
		US-			
·		US-			
		US-			

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3 -</sup> Number <sup>4 -</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	
		WO 9911628	02/1999	Guilford Pharmaceticals		
		WO 9962908	12/1999	Abbott Laboratories		
		WO 0059509	10/2000	Novartis		
		WO 0110859	02/2001	Bayer Corporation		

Examiner	Date	
Signature	Considered	
l "		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	Substitute for form 1449/PTO			Complete if Known			
				Application Number	10/720,702		
INF	ORMATION	DIS	SCLOSURE	Filing Date	November 24, 2003		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Jacques P. Dumas		
	(I lee as many sha	ante se i	nacassary)	Art Unit	1621		
(Use as many sheets as necessary)				Examiner Name	Peter G. O'Sullivan		
Sheet	4	of	9	Attorney Docket Number	5052D1(304795/69713 Div)	フ	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Biagi et al., Chemical Abstracts, Vol. 126:89328, 1996.	
		Biagi et al., Chemical Abstracts, Vol. 123:83329, 1995.	
		Biagli et al., Chemical Abstracts, Vol. 123:111969, 1995.	
		Monge et al., Chemical Abstracts, Vol. 120:95169, 1994.	
;····•(4)		Marchard et al., Chemical Abstracts, Vol. 114:42612, 1991.	
· · · · · · · · · · · · · · · · · · ·		Andersen et al., Chemical Abstracts, Vol. 112:55749, 1990.	
		Suzuki et al., Chemical Abstracts, Vol. 90:152107, 1979.	
		Mitsuhashi et al., Chemical Abstracts, Vol. 84:180170, 1976.	
		Mitsuhashi et al., Chemical Abstracts, Vol. 84:180170, 1976.	
		Sieja, Chemical Abstracts, Vol. 78:137957, 1973.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a velid OMB part of the contains a velid OMB part Under the Panerwork Reduction Act of 1995, no persons are required to re

Substitu	ite for form 1449/PTO		,	Complete if Known			
Cubolito	10 10/110/11 1440/1 10			Application Number	10/720,702		
INF	ORMATION	I DIS	CLOSURE	Filing Date	November 24, 2003		
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Jacques P. Dumas		
	(Use as many she	aate ae n	eccessary)	Art Unit	1621		
	Ose as many sne	reis as n	ecessary)	Examiner Name	Peter G. O'Sullivan		
Sheet	5	of	9	Attorney Docket Number	5052D1(304795/69713 Div)		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Pons et al., Chemical Abstracts, Vol. 71:81350, (1969)	
		Howe et al., Chemical Abstracts, Vol. 71:21922, (1969)	
		Robba et al., Chemical Abstracts, Vol. 69:10411, (1968)	
		Robba et al., Chemical Abstracts, Vol. 66:95066, (1967)	
		Robba et al., Chemical Abstracts, Vol. 66:94981, (1967)	
		Desimoni et al., Chemical Abstracts, Vol. 66:55454, (1967)	
		Chemical Abstract: 15:256197; Uenishi, Keiji et al. "Preparations of 1(3-pyridylmethyl) phthalazines as blood platelet aggregation inhibitors", Jpn. Kokai Tokkyo Koho, 6 pp 1992	
		Ferrara, N. et al., "Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins". Endocrine Reviews, 13, 18-32 (1992)	
		Neufeld, G. et al., "Vascular endothelial growth factor (VDGF) and its receptors". FASEB J., 13, 9-22 (1999).	
		Shweiki, D. et al., "Vascular Endothelial growth factor induced by hypoxia may mediate hypoxia-initated angiogenesis". Nature, 359, 843-848, (1992)	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449/PTO			Complete if Known		
		וחו	CCL OCUDE	Application Number	10/720,702	
	NFORMATION			Filing Date	November 24, 2003	
5	TATEMENT E	3 Y /	APPLICANT	First Named Inventor	Jacques P. Dumas	
	(Use as many sho	eets as	s necessary)	Art Unit	1621	
		•		Examiner Name	Peter G. O'Sullivan	
Sheet 6 of		9	Attorney Docket Number	5052D1(304795/69713 Div)		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Mustonen, T. and Alitalo K., "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis". Cell Biology, 129, 895-898 (1995)	
		Waltenberger, J. et al., "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor" J. Biol. Chem. 269, 26988-26995, 1994	
		Seetharan, L. et al., "A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF". Oncogene, 10, 135-147 (1995)	
		Shweiki, D. et al., "Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis". Proc. Nat'l. Acad. Sci. USA, 92, 768-772 (1995).	
		Grugel, S. et al., "Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells," J. Biol. Chem., 270, 25915-25919 (1995)	
		Rak, J. et al., "Mutant ras Oncogenes Upregulate VEGF/VPF Expression: Implications for Induction and Inhibition of Tumor Angiogenesis." Cancer Research 55, 4575-4580 (1995).	
		Mattern, J., et al., "Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma." Brit. J. Cancer, 73, 931-934 (1996)	
		Viglietto, G. et al., "Upregulation of vascular endothelial growth factor (VDGF) and downregulation of placenta growth factor (PIGF) associated with malignancy injuman thyroid tumors and cell lines". Oncogene, 11, 1569-1579 (1995).	
		Brown, L. et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Breast Cancer". Human Pathology, 26, 86-91 (1995).	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/720,702	
11	NFORMATION	I DI	SCLOSURE	Filing Date	November 24, 2003	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Jacques P. Dumas	
				Art Unit	1621	
	(Use as many sh	eets as	necessary)	Examiner Name	Peter G. O'Sullivan	
Sheet 7		of	9	Attorney Docket Number	5052D1(304795/69713 Div)	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<b>T</b> <sup>2</sup>
		Brown, L. et al., "Expression of Vascular Permeability Factor (Vascular Endothethiel Growth Factor) and its Receptors in Adrenocarinomas of the Gastrointestinal Tract". Cancer Research 53, 4727-4735 (1993)	
		Suzuki, K. et al., "Expression of Vascular Permeability Factor/Vascular Endothelial Growth Factor in Human Hepatocellular Carcinoma", Cancer Research, 56, 3004-3009 (1996)	
		Brown, L, et al., "Increased Expression of Vascular Permeability Factor (Vascular Endothelial growth Factor) and its Receptors in Kidney and Bladder Carcinomas", Am. J. Pathology, 143, 1255-1262 (1993)	
		Olson, T. et al., "Vascular Permeability Factor Gene Expression in Normal and Neoplastic Human Ovaries", Cancer Research, 54, 276-280 (1994)	
		Guidi, A. J. et al., "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Expression and Angiogenesis in Cervical Neoplasia", J. Nat'l. Cancer Institute, 87; 1237-1245 (1995)	
		Hashimoto, M. et al., "Expression of Vascular Endothelial Growth Factor and its Receptor mRNA in Angiosarcoma". Laboratory Investigation, 83, 859-863, (1995)	
		Plate, Karl H. et al., "Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo". Nature, 359, 845-848 (1992)	
		Phillips, Heidi S. et al., "Intense focal expression of vascular endothelial growth factor mRNA in human intracranial neoplasms: association with regions of necrosis". Int. J. Oncology, 2, 913-919 (1993)	
		Berkman, Richard A., et al., "Expression of the Vascular Permeability Factor/Vascular Endothethial Growth Factor Gene in Central Nervous System Neoplasms", J. Clin. Invest. 91, 153-159 (1993)	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/720,702	
IN	NFORMATION	1 DI	SCLOSURE	Filing Date	November 24, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Jacques P. Dumas	
				Art Unit	1621	
	(Use as many sh	eets as	s necessary)	Examiner Name	Peter G. O'Sullivan	
Sheet	8 of		9	Attorney Docket Number	5052D1(304795/69713 Div)	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<b>T</b> <sup>2</sup>
		Kim K. Jin, et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo," Nature, 362, 841-844 (1993).	
		Rockwell, P. and Goldstein, N. I., "Role of Protein Tyrosine Kinase Receptors in Cancer; Possibilities for Therapeutic Intervention", Mol. and Cell. Differ., 3, 315-335 (1995).	
metrorial uniformi		Aiello, L. P., et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and other Retinal Disorders". New England J. Med., 331, 1480-1487 (1994)	
		Pe'er, J., et al., "Hypoxia-Induced Expression of Vascular Endothelial Growth Factor by Retinal Cells is a Common Factor in Neovascularizing Ocular Diseases", Lab. Invest., 72, 638-645 (1995).	000
		Lopez, P. F. et al., "Transdifferentitated Retinal pigment Epithelial Cells are Immunoreactive for Vascular Endothelial Growth Factor in Surgically Excised Age-Related Macular Degeneration-Related Choroidal Neovascular Membranes". Invest Opthamol. Vis. Sci., 37, 855-868 (1996).	
		Koch, A. E. et al., "Vascular Endothelial Growth Factor: A Cytokine Modulating Endothelial Function in Rheumatoid Arthritis," J. Immunol., 152, 4149-4156 (1994).	
		Peacock, D. J., et al., "Angiogenesis Inhibition Suppresses Collagen Arthritis", J. Exp. Med., 175, 1135-1138, (1992)	
		Brown, L., et al., "Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Bullous Pemphigoid, Dermatities Herpetiformis, and Erythema Multiforme", J. Invest. Dermatol., 194, 744-749 (1995).	
		El-Feky, S.A, "Phthalazine Derivatives from 1-Hydrazino 4-Benzyl (or Methyl) Phthalizine", Egypt J. Chem., 33, 189-197 (1990).	

Examir	er	Date	
Signatu	re I	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/720,702	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	November 24, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Jacques P. Dumas	
				Art Unit	1621	
(Use as many sheets as necessary)				Examiner Name	Peter G. O'Sullivan	
Sheet	9	of	9	Attorney Docket Number	5052D1(304795/69713 Div)	

·		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Duhault, J. et al., "Etude D'Hydrazones Heterocycliques de Pyridoxal Phosphate. Comportement Coenzymatique", Bull Soc. Chim. Biol. 49, 177-0190 (1967)	
		Holava, H.M. and Partyka, R.A., "1-Substituted 4-Aryl-(or 4-Arylalkyl-) Phthalazines", J. Med. Chem, 12, 555-556 (1969)	
		Gerhardt, et al., Imidazo[4,5,d]pyridazines. IV. Synthesis Of 4,7-Disubstituted Derivatives and 1-Benzyl-2-Substituted Thio Derivatives, J. Heterocyclic Chem., 2, 247-252 (1965)	
		Malm, et al., Imidazo[4,5,d]pyridazines. III. The Synthesis of 2- Phenylimidazo[4,5,d]pyridazines. J. Heterocyclic Chem., 1, 182-185 (1964)	
		Laursen, et al., Synthesis of 2,4,7-Trichloroimidazo[4,5,d]pyridazine and Certain of its Derivatives. J. Org Chem., 27, 2500-2504 (1962)	
		Biagi, et al., 1,2,3- Triazole[4,5-d]pyridazinesIV. Preparation and Adenosine Receptor Binding of New 4 and/or 7 Amino-derivatives. Il Farmaco, 50, 99-105 (1995)	
		Majcen, et al., Pyridazines., LXIX. Annealation of an azole ring to 1,2,5- Thiadiazolo[3,4-d]pyridazine. Chem. Abstracts 83: 79175f (1975)	
		Robba et al., Thieno[2,3-d]pyridazines and thieno[3,4-d]pyridazines. Chem. Abstracts 69:10411y (1968)	
		Desimoni, et al., Polynuclear isoxazole types II. Isoxazolo[4,5-d]pyridazines. Chem. Abstracts 66: 5545u (1967)	

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.